Is Dapagliflozin propanediol a new hope for the treatment of diabetes?

Simply put, diabetes is a condition with too much sugar in the bloodstream. Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or the body cannot effectively use the insulin produced. Insulin is a hormone that regulates blood sugar. Hyperglycemia, or elevated blood sugar, is a common consequence of uncontrolled diabetes. Over time can cause severe damage to many of the body's systems (especially the nerves and blood vessels).

For the treatment of diabetes, there are two main ways to control blood sugar and blood pressure, especially for type 1 diabetics. Type 1 diabetics need insulin injections, and type 2 diabetics may be treated with oral medications but may also need insulin therapy. According to recent medical studies, Dapagliflozin propanediol is very effective in treating diabetes. Let's give you more details about this new medicine.

What is Dapagliflozin propanediol?

Dapagliflozin propanediol exists mainly in the form of a monohydrate, consisting of Dapagliflozin compounded with (S)-propanediol and a hydrate in the ratio (1:1:1). It is used to improve glycemic control in adult patients with type 2 diabetes, in conjunction with diet and exercise. It acts as a hypoglycemic agent and sodium-glucose transporter protein subtype two inhibitor. It contains a Dapagliflozin and an (S)-propane-1,2-diol.

Biochemical Properties of Dapagliflozin

Dapagliflozin is an orally active, potent, and selective inhibitor of the renal sodium-dependent glucose cotransporter. Dapagliflozin reduces blood glucose levels by blocking the renal process of glucose reabsorption and promoting glucose excretion in the urine, with good pharmacokinetic properties and oral availability in vivo.

The medical use of Dapagliflozin propanediol is often oral. It works by inhibiting the SGLT2 enzyme, which is responsible for glucose reabsorption from the kidneys. By inhibiting this enzyme, glucose will be excreted from the urine, and blood glucose levels will decrease.

Dapagliflozin propanediol also has the advantage that it has a low bioavailability which can be improved by taking it with food. The drug has been shown to have a longer elimination half-life than canagliflozin and empagliflozin. Dapagliflozin has been shown to have a higher potency than metformin hydrochloride in vitro. In combination with metformin, the standard therapeutic dose of Dapagliflozin of 10 mg per day resulted in a 0.54-0.84 percentage point reduction in HbA1c in patients with poorly controlled type 2 diabetes and normal renal function compared to metformin monotherapy.

Prospects and Outlook

Scientists at Benchchem found that the protective effect of Dapagliflozin propanediol against heart failure is mainly attributable to the hemodynamic effect, whereby SGLT2 inhibitors effectively reduce intravascular volume through osmotic diuresis and diuresis. As a result, this may reduce preload and afterload, thereby reducing the heart's workload and improving left ventricular function.

It is because of the tremendous effect of Dapagliflozin Propanediol in improving type 2 diabetes in adults that it is believed that shortly this drug will become a boon for the majority of diabetic patients.